Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus SYNALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus SYNALAR.
ASMANEX TWISTHALER vs SYNALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
Apply a thin layer to affected area twice daily. Max 60 g/week.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
Terminal elimination half-life: 1-2 hours (topical use); 3-4 hours (systemic absorption after topical application to large areas or occluded skin). Clinical context: short half-life allows once- or twice-daily dosing.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal: <1% as unchanged drug; biliary/fecal: minimal; primarily hepatic metabolism with metabolites excreted renally.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid